Press Releases May 14, 2026 04:30 PM

Aspen Aerogels Begins Staged Restart of East Providence Facility

Aspen Aerogels Commences Phased Restart of East Providence Manufacturing Facility Following Safety Review

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
ASPN

Aspen Aerogels has initiated a staged restart of its East Providence, Rhode Island manufacturing facility after thorough mechanical, operational, and safety inspections conducted in coordination with local, state, and federal agencies following an incident on April 8th. The company plans a phased ramp-up to full production over time, prioritizing employee and community safety.

Aspen Aerogels Begins Staged Restart of East Providence Facility
ASPN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Aspen Aerogels begins phased restart of East Providence facility after comprehensive safety and operational reviews post-incident.
  • Company emphasizes safety and community collaboration during the restart process.
  • Aspen leverages its Aerogel Technology Platform serving sectors such as clean energy, e-mobility, and energy infrastructure.
  • Sectors impacted include manufacturing, clean energy, electric vehicle supply chain, and industrial safety compliance.

NORTHBOROUGH, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the "Company") today announced the successful initiation of a staged restart of its manufacturing operations at its East Providence, Rhode Island facility.

The restart began after comprehensive mechanical, operational, and safety reviews conducted in close coordination with local, state, and federal agencies following the incident on April 8th. During this period, Aspen completed rigorous inspections of the facility, executed detailed safety reviews of all equipment, and conducted extensive equipment testing so that the plant meets all operational standards necessary for restart. The company will proceed with a deliberate, phased ramp-up of production, and expects that returning the facility to its full capabilities will take time.

"We deeply value our place in the East Providence community. Our absolute first priority remains the safety of our employees and our neighbors as we methodically bring our facility back online," said Don Young, President and CEO. "I also want to express our sincere gratitude to Mayor DaSilva, Fire Chief Carey, and Building Official Walker and their teams for their invaluable partnership throughout this process. Their collaboration, alongside the tireless dedication of our own Aspen team, has been essential to develop a safe and responsible restart plan."

About Aspen Aerogels, Inc.
Aspen is a technology leader in sustainability and electrification solutions. The Company's aerogel technology enables its customers and partners to achieve their own objectives around the global megatrends of resource efficiency, e-mobility and clean energy. Aspen's PyroThin® products enable solutions to thermal runaway challenges within the electric vehicle ("EV") market. The Company's Cryogel® and Pyrogel® products are valued by the world's largest energy infrastructure companies. Aspen's strategy is to partner with world-class industry leaders to leverage its Aerogel Technology Platform® into additional high-value markets. Aspen is headquartered in Northborough, Mass. For more information, please visit www.aerogel.com.

Special Note Regarding Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding the Company’s belief that it will ramp up production following the restart of operations at its manufacturing facility in East Providence, Rhode Island; the Company’s expectation regarding its ability to restore the East Providence manufacturing facility to its full capabilities and the time it will take to do so; the Company’s ongoing investigation of the incident at the manufacturing facility; the Company’s leveraging of the capacity of its external manufacturing partner to help support customer demand; and the potential impacts of the incident on the Company’s business, operations and financial performance. These statements are based on the Company’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the Company’s ability to resume operations at the facility; the Company’s ability to manufacture the full array of its products at the facility and to meet expected customer demand; the Company’s ability to mitigate any potential impacts on the Company’s business, operations and financial performance; as well as the risks described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contacts:
Neal Baranosky
Phone: (508) 691-1111 x 8
nbaranosky@aerogel.com

Georg Venturatos / Patrick Hall
Gateway Group
Phone: (949) 574-3860
ASPN@gateway-grp.com

Media Contact:
Mike Raia
(401) 340-9425
mike@halfstreetgroup.com


Risks

  • Uncertainty regarding the time required to restore full production capabilities at East Providence facility may affect supply commitments.
  • Potential ongoing impacts on business operations and financial performance due to the incident and phased restart.
  • Dependence on external manufacturing partners to meet customer demand introduces operational risks.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026